Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
about
Advances and hurdles on the way toward a leprosy vaccine.BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy controlThe continuing challenges of leprosyProtective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcerThe Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosisEffect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccinationProfile: the Karonga Health and Demographic Surveillance SystemRe-emergence of tuberculosis and its variants: implications for dentistry.Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance.Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.Risk factors for buruli ulcer: a case control study in Cameroon.BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model.Specificity and function of immunogenic peptides from the 35-kilodalton protein of Mycobacterium lepraeSafety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.Case control study to determine the factors associated with leprosy in the sene district, brong ahafo region of ghana.Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy.Distribution of environmental mycobacteria in Karonga District, northern Malawi.Immunostimulatory activity of recombinant Mycobacterium bovis BCG that secretes major membrane protein II of Mycobacterium leprae.Infection of SCID mice with Mycobacterium leprae and control with antigen-activated "immune" human peripheral blood mononuclear cellsWhat has Karonga taught us? Tuberculosis studied over three decades.Epidemiology of Tuberculosis in MalawiManagement and outcome of Bacille Calmette-Guérin vaccine adverse reactions.The success and failure of BCG - implications for a novel tuberculosis vaccine.Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.Risk and protective factors for leprosy development determined by epidemiological surveillance of household contactsProtective efficacy of BCG vaccine against leprosy in southern Malaŵi.Tropical respiratory medicine. 2. Impact of human immunodeficiency virus on tuberculosis in developing countriesTranslational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.Effects of antenatal and postnatal environments on CD4 T-cell responses to Mycobacterium bovis BCG in healthy infants in the Gambia.Recent advances in tropical medicineMajor histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection.Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection.Inhibition of the multiplication of Mycobacterium leprae by vaccination with a recombinant M. bovis BCG strain that secretes major membrane protein II in mice."To BCG or not to BCG, that is the question!". The challenge of BCG vaccination: Why can't we get it right?A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses.Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.Prevalence and distribution of non-tuberculous mycobacteria (NTM) in cattle, African buffaloes (Syncerus caffer) and their environments in South Africa.
P2860
Q22305432-A8BA5F7A-0C2A-4413-82A2-63EA53AFA387Q22305924-31BFAAAE-A22D-401A-AC2C-4311C63E7F40Q24545809-9BAEEBCA-08A9-4432-8065-A223806A68BAQ24548647-4F6D32DB-E50C-4BEC-81C8-89D1ECEF1BE2Q26852552-2F553313-19C7-4024-8D32-8E0FE0743168Q28350972-B5330717-2A62-4DC4-8482-1B81421B6A7CQ28727176-7EBDAC9A-0326-4FDB-9966-4EDDB16625D0Q30332195-413DFA92-2955-471D-8690-F542F5157EE4Q30362107-99B42186-BD6E-4E67-8ED0-51F8B052A358Q30408875-F9D0605F-493D-41AD-8AD4-B7C9D6019170Q33312434-5C2A6FBD-D73E-49A4-9FE2-A3E4FBDA6B7DQ33851427-442B2807-19F7-4109-85E1-CAC0B73FA93BQ33933553-404B3847-31C3-486B-9F6C-A0BBE82E5BEEQ34000740-300347AB-7B99-40CB-A63C-F0B125E17AAAQ34055234-5B8B2A12-F67B-46FB-80E8-17C8934B5CDFQ34378413-0377065E-B717-4626-8202-B942469C8101Q34389901-5D53B9FA-B559-4C08-8EA4-353364CD2F58Q34536007-D2C563D5-B4AD-48FD-BBF4-DB6ADD4A321CQ34570558-B9381193-AD06-4EA1-AFD3-012033837D73Q35217560-237761F0-78B2-485D-BF1E-982E7BA0B5F3Q35394786-6060C751-F87F-48B6-92CB-394457017FDDQ35737870-11112F07-5228-4084-B504-0FD96F50AEC2Q35937995-20CB1086-399D-4E11-B42D-6D819719F05CQ36092315-478BADBB-E679-4F39-8564-24C3179BCCA4Q36191944-F3F982ED-0F94-446F-BF16-90FDCBCDFBFCQ36229621-5385488F-8F3B-410B-8736-ABB83A611522Q36422533-01783916-C24C-4890-8DEA-C2D6FD903013Q36503354-E6AD25B5-F978-4357-A3F9-FDFBD6E4A6FEQ36566506-3277B4E7-213F-4C97-8BA6-1CFCC517F335Q36736465-B6C2F019-C0C6-45F0-B834-51BA5318AFD2Q36746866-85A09DF2-9FD9-4C05-874F-EAF8914E216FQ36886014-24C05ABD-2FD9-4784-9BDA-0AFCABF9DBF2Q37269276-0F83E375-935B-4F54-B3DA-FB4327E8B37BQ37309256-291803D4-B584-4240-87B5-DD215B35D9F5Q37374687-DE5FF933-E23C-4703-A01A-3147151C6B92Q37473072-3A437784-4B1E-4415-A4DB-70CD1806CA0FQ37623702-FD1BDC4C-D26B-48B0-BA42-95C501ECFE61Q37704447-2B9D546B-BF86-4E36-A0E9-332AD60B32D7Q38886409-27E4315F-3279-4197-BB8F-577E59CF4E71Q39019441-F39FA2BB-3C49-4E61-91C1-323FCCBA3F72
P2860
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@en
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@nl
type
label
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@en
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@nl
prefLabel
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@en
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@nl
P2093
P921
P1433
P1476
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
@en
P2093
J A Sterne
J M Pönnighaus
N G Liomba
P A Jenkins
R J Wilson
P304
P356
10.1016/0140-6736(92)90794-4
P407
P577
1992-03-01T00:00:00Z